HALO stock forecast
Our latest prediction for Halozyme Therapeutics, Inc.'s stock price was made on the Aug. 28, 2018 when the stock price was at 18.06$.
In the short term (2weeks), HALO's stock price should underperform the market by 0.00%. During that period the price should oscillate between -4.80% and +4.98%.
In the medium term (3months), HALO's stock price should outperform the market by 3.30%. During that period the price should oscillate between -11.94% and +17.37%.Get email alerts
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
At the moment the company generates 178M USD in revenues.
On its last earning announcement, the company reported a loss of -0.36$ per share.
The book value per share is 1.77$
Three months stock forecastAug. 28, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|